TransMedics Group Management
Management criteria checks 2/4
TransMedics Group's CEO is Waleed Hassanein, appointed in Aug 1998, has a tenure of 27.67 years. total yearly compensation is $10.92M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 1.63% of the company’s shares, worth $57.14M. The average tenure of the management team and the board of directors is 3.3 years and 12.5 years respectively.
Key information
Waleed Hassanein
Chief executive officer
US$10.9m
Total compensation
| CEO salary percentage | 7.12% |
| CEO tenure | 27.7yrs |
| CEO ownership | 1.6% |
| Management average tenure | 3.3yrs |
| Board average tenure | 12.5yrs |
Recent management updates
Recent updates
TMDX: Clinical Trials And 2026 Outlook Will Drive The Next Leg
Analysts have increased the implied fair value for TransMedics Group to $118 from $114, citing refreshed models after Q4 results, updated 2026 outlooks, and a series of revised price targets across the Street that incorporate changes to growth, margin, and future P/E assumptions. Analyst Commentary Street research on TransMedics Group has centered on refreshed models after Q4 results, with several firms updating price targets as they revisit assumptions around growth, profitability, and the appropriate P/E range for the stock.TransMedics: Revolutionizing The Organ Transplant Market While Trading At A Discount
Apr 24
TMDX: Organ Platform Expansion And Trials Will Support Future Repricing
Analysts have adjusted their price targets on TransMedics Group in a wide range, with some cuts such as Evercore ISI's $52 reduction and several increases up to $175. These changes reflect updated models following Q4 results, guidance, and ongoing investment in heart, lung, and kidney programs.TMDX: Organ Platform Expansion And Trials Will Drive Future Repricing
Analysts have lifted their price targets on TransMedics Group into a roughly $130 to $175 range, citing Q4 results that beat expectations, a stronger than expected 2026 outlook, ongoing investment in heart and lung transplant programs with kidney next in line, and expansion efforts, while the updated model here keeps fair value at $190 with only minor tweaks to revenue growth, discount rate and profit margin assumptions. Analyst Commentary Recent Street research reflects a generally constructive tone around TransMedics Group, with several bullish analysts lifting price targets into a higher range after reviewing Q4 results, updated guidance and the expanding transplant platform.TMDX: Organ Platform Execution And Trials Will Drive Future Repricing
Analysts have modestly lifted their price targets on TransMedics Group, with recent moves ranging from $130 to $175. This reflects updated models after Q4 results, stronger 2026 outlook commentary and ongoing investment in building out heart, lung and kidney platforms.TMDX: Margin Upside And Organ Platform Expansion Are Expected To Drive Repricing
The analyst price target for TransMedics Group in our framework has shifted to $190 from $170, reflecting updated Street research that points to stronger margin potential, ongoing investment in heart and lung, and supportive recent quarterly results and guidance. Analyst Commentary Recent Street research on TransMedics Group has leaned constructive, with several bullish analysts revisiting their models after quarterly results and updated guidance.
TMDX: Competitor Clearance And New Campus Will Shape Balanced Future Prospects
Analysts have nudged their $144.20 price target on TransMedics Group slightly higher, citing the recent selloff on competitor clearance as unwarranted and maintaining broadly similar assumptions around growth, profitability and future P/E levels. Analyst Commentary Analysts reviewing the recent move in TransMedics Group generally view the competitor clearance as more of a sentiment shock than a change in the company’s core outlook, and they have adjusted their models around valuation and execution rather than rewriting the growth story.TMDX: Competitor Clearance And New Headquarters Will Shape Future Transplant Opportunity
Analysts trimmed their price target for TransMedics Group slightly to about US$144 from roughly US$145, citing updated fair value estimates and reaffirming their view that the recent selloff following competitor news was unwarranted. Analyst Commentary Analysts reviewing the recent stock move around competitor news describe the TransMedics Group selloff as unwarranted, arguing that the updated fair value work supports only a very small trim to the price target rather than a major reset.TMDX: Expanding Trials And New Headquarters Will Shape Future Transplant Opportunity
Narrative Update: TransMedics Group (TMDX) Analysts have nudged their price target on TransMedics Group higher to about US$145, citing expectations for Q3 U.S. sales to exceed consensus, potential contribution from upcoming heart and lung clinical trials and international expansion in 2026, and rapidly improving margins in what they view as a still underpenetrated transplant market. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target of US$148 as reflecting stronger execution potential, with Q3 U.S. sales expectations above current consensus estimates.TMDX: Expanding Trials And International Reach Will Drive Future Transplant Volume Upside
Analysts have nudged their fair value estimate for TransMedics Group slightly higher to about $145, supported by a new $148 price target and expectations for stronger U.S. Q3 sales, upcoming heart and lung clinical trials, faster margin improvement, and international expansion. Analyst Commentary Bullish Takeaways Bullish analysts see the new $148 price target as reflecting higher conviction that the updated fair value near $145 is supported by the current execution plan and outlook for U.S. Q3 sales.Here's Why TransMedics Group (NASDAQ:TMDX) Can Manage Its Debt Responsibly
Dec 30
TMDX: Regulatory Reforms Will Drive Future Transplant Volume Upside
Analysts have modestly raised their price target on TransMedics Group to about $145 from about $142, citing expectations for U.S. sales outperformance, accelerating margins, a strong competitive position in an underpenetrated transplant market, and potential upside from regulatory reforms and new clinical trials. Analyst Commentary Bullish analysts point to a combination of stronger than expected U.S. demand, accelerating profitability, and favorable policy tailwinds as key drivers supporting higher valuation multiples for TransMedics Group.TMDX: Clinical Trial Progress And US Market Dynamics Will Shape 2025 Outlook
Analysts have raised their price target for TransMedics Group from $141.91 to $148, citing anticipated U.S. sales outperformance, clinical trial momentum, and benefits from industry reforms as key drivers of this positive revision. Analyst Commentary Analyst sentiment on TransMedics Group is diverse, with research notes highlighting both significant strengths and noteworthy challenges for the company's future outlook and valuation.TMDX: Expanding Regulatory Reforms Will Drive U.S. Organ Transplant Opportunity Forward
Analysts have raised their price target for TransMedics Group from $141.91 to a range between $148 and $170, citing stronger-than-expected U.S. sales, rapid margin improvement, and anticipated benefits from regulatory reforms and clinical advancements. Analyst Commentary Recent Street research provides a mixed, but largely positive, outlook on TransMedics Group, highlighting both key growth drivers and areas of potential caution as the company targets an expanding opportunity in organ transplantation.TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction
Analysts have raised their price target for TransMedics Group from $138.88 to $141.91 per share, citing expectations for stronger U.S. sales, new clinical trials, growing international momentum, and a rapidly expanding addressable market as key drivers of potential upside. Analyst Commentary Recent Street research on TransMedics Group reflects both optimism around near-term growth opportunities and a degree of caution regarding potential competitive and market challenges.Organ Transplant Demand And International Expansion Will Unlock Future Opportunities
Analysts have trimmed their price targets for TransMedics Group to $138.88 amid growing concerns about competitive pressures and mixed surgeon feedback on the OCS platform, despite continued confidence in company growth, reflecting a modest downward revision in fair value. Analyst Commentary Bullish analysts cite TransMedics as a best-in-class growth story, raising price targets following strong results.TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 38% Share Price Bounce
May 30Additional Considerations Required While Assessing TransMedics Group's (NASDAQ:TMDX) Strong Earnings
May 15An Intrinsic Calculation For TransMedics Group, Inc. (NASDAQ:TMDX) Suggests It's 30% Undervalued
May 03TransMedics: Downgrading To Sell As Growth Hurdles Mount
Apr 22TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 15TransMedics: The Financial Tipping Point That Will Drive Mass Adoption
Mar 31TransMedics: A Very Bullish Last Few Months Could Change Sentiment
Mar 20TransMedics: Aggressive Guidance Largely Ignored By The Market
Mar 03TransMedics: Big Growth And Operational Advantages, Buy This Leading Medical Player
Feb 23TransMedics Group, Inc.'s (NASDAQ:TMDX) 26% Jump Shows Its Popularity With Investors
Feb 16Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Jan 19TransMedics: Misplaced Fear
Jan 16Breaking Into Healthcare: Why TransMedics Is My Bold First Move
Jan 05With A 30% Price Drop For TransMedics Group, Inc. (NASDAQ:TMDX) You'll Still Get What You Pay For
Dec 28TransMedics Faces Market Turbulence As Growth Engines Stutter
Dec 04These 4 Measures Indicate That TransMedics Group (NASDAQ:TMDX) Is Using Debt Reasonably Well
Nov 20TransMedics: Long-Term Thesis Hasn't Changed At All
Nov 19TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
Nov 12What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash
Oct 30TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
Oct 29TransMedics' Organ Care: Critical Innovation With Lofty Expectations
Oct 23TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
Oct 16Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10
Expanding Aviation And OCS Technologies Forecasts Bright Horizon For Medical Logistics Growth
Expanding services and market share through the aviation fleet, technological advancements, and new clinical programs is expected to bolster revenue growth and margins.TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$11m | US$777k | US$190m |
| Sep 30 2025 | n/a | n/a | US$92m |
| Jun 30 2025 | n/a | n/a | US$72m |
| Mar 31 2025 | n/a | n/a | US$49m |
| Dec 31 2024 | US$8m | US$688k | US$35m |
| Sep 30 2024 | n/a | n/a | US$33m |
| Jun 30 2024 | n/a | n/a | US$3m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$7m | US$634k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$575k | -US$36m |
| Sep 30 2022 | n/a | n/a | -US$42m |
| Jun 30 2022 | n/a | n/a | -US$48m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$7m | US$535k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$30m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$2m | US$534k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$36m |
| Dec 28 2019 | US$3m | US$449k | -US$34m |
Compensation vs Market: Waleed's total compensation ($USD10.92M) is above average for companies of similar size in the US market ($USD7.12M).
Compensation vs Earnings: Waleed's compensation has increased by more than 20% in the past year.
CEO
Waleed Hassanein (57 yo)
27.7yrs
Tenure
US$10,915,533
Compensation
Dr. Waleed H. Hassanein, M.D., is the Founder of Transmedics Group, Inc. and has been its President, Chief Executive Officer and Director since August 1998. He founded TransMedics, Inc. in August 1998 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 27.7yrs | US$10.92m | 1.63% $ 57.1m | |
| CFO & Treasurer | 1.3yrs | US$1.57m | 0.0087% $ 303.3k | |
| Senior Vice President of Supply Chain & Operations | 3.3yrs | US$2.82m | 0.042% $ 1.5m | |
| Senior Vice President of International | 20.3yrs | US$3.75m | 0.044% $ 1.5m | |
| Advisor | less than a year | US$1.50m | 0.013% $ 463.8k | |
| Senior VP | less than a year | no data | no data | |
| Vice President of Global Regulatory Affairs | 6.8yrs | US$813.47k | no data |
3.3yrs
Average Tenure
55yo
Average Age
Experienced Management: TMDX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 27.7yrs | US$10.92m | 1.63% $ 57.1m | |
| Independent Director | 22.3yrs | US$328.21k | 0.88% $ 30.9m | |
| Independent Director | 5.3yrs | US$354.17k | 0.0056% $ 194.8k | |
| Independent Chairman | 14.8yrs | US$399.21k | 0.53% $ 18.5m | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 10.2yrs | US$345.05k | 0.0021% $ 74.2k | |
| Independent Director | 9.7yrs | US$354.77k | 0.0056% $ 194.8k |
12.5yrs
Average Tenure
71yo
Average Age
Experienced Board: TMDX's board of directors are seasoned and experienced ( 12.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/29 11:08 |
| End of Day Share Price | 2026/04/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TransMedics Group, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| William Plovanic | Canaccord Genuity |
| Daniel Markowitz | Evercore ISI |